Management of liver disease and portal hypertension in cystic fibrosis: a review

References

• Colombo C, Battezzati PM. Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol. 2004;41(6):1041–1044. doi: 10.1016/j.jhep.2004.10.002
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation Patient Registry. 2022 Annual Data Report. Cystic Fibrosis Foundation Publications; 2022, [Online]. Available from: https://www.idtheftcenter.org/post/identity-theft-resource-center-2021-annual-data-breach-report-sets-new-record-for-number-of-compromises/
   Google Scholar
• Hisert KB, Birket SE, Clancy JP, et al. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respir Med. 2023;11:916–931. doi: 10.1016/S2213-2600(23)00324-7
   PubMed Web of Science ®Google Scholar
• Debray D, Narkewicz MR, Bodewes FAJA, et al. Cystic fibrosis-related liver disease: research challenges and future perspectives. J Pediatr Gastroenterol Nutr. 2017;65(4):443–448. doi: 10.1097/MPG.0000000000001676
   PubMed Web of Science ®Google Scholar
• Dana J, Debray D, Beaufrère A, et al. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol. 2022;76(2):420–434. doi: 10.1016/j.jhep.2021.09.042
   PubMed Web of Science ®Google Scholar
• Dajti E, Ravaioli F, Paiola G, et al. The non-invasive evaluation of liver involvement in patients with cystic fibrosis: a prospective study. Liver Int. 2023;43(11):2492–2502. doi: 10.1111/liv.15748
   PubMedGoogle Scholar
• ONeill JP, Clifford CS, Nolan NP, et al. Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis. Ir J Med Sci [Internet]. 2023;192(4):1657–1660. doi: 10.1007/s11845-022-03153-0
   PubMed Web of Science ®Google Scholar
• Elkrief L, Lazareth M, Chevret S, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Hepatology. 2021;74(1):364–378. doi: 10.1002/hep.31688
   PubMed Web of Science ®Google Scholar
• Hillaire S, Cazals-Hatem D, Bruno O, et al. Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy. Liver Transpl. 2017;23(10):1342–1347. doi: 10.1002/lt.24842
   PubMed Web of Science ®Google Scholar
• Wu H, Vu M, Dhingra S, et al. Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension. Clin Gastroenterol Hepatol. 2019;17(10):2134–2136. doi: 10.1016/j.cgh.2018.10.046
   PubMed Web of Science ®Google Scholar
• Witters P, Libbrecht L, Roskams T, et al. Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. J Cystic Fibrosis. 2017;16(5):e11–3. doi: 10.1016/j.jcf.2017.03.006
   PubMedGoogle Scholar
• Cohn JA, Strong TV, Picciotto MR, et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105(6):1857–1864. doi: 10.1016/0016-5085(93)91085-V
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, LaRusso NF. The Cholangiopathies. Mayo Clin Proc. 2015 Jun;90(6):791–800. Epub 2015 May 6. PMID: 25957621; PMCID: PMC4533104. doi: 10.1016/j.mayocp.2015.03.017
   PubMed Web of Science ®Google Scholar
• Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2018;34(3):146–151. doi: 10.1097/MOG.0000000000000432
   PubMed Web of Science ®Google Scholar
• Fiorotto R, Villani A, Kourtidis A, et al. The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology. 2016;64(6):2118–2134. doi: 10.1002/hep.28817
   PubMed Web of Science ®Google Scholar
• Flass T, Tong S, Frank DN, et al. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLOS One. 2015;10(2):1–18. doi: 10.1371/journal.pone.0116967
   Web of Science ®Google Scholar
• Fiorotto R, Strazzabosco M. Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota. Cell Mol Gastroenterol Hepatol. 2019;8(2):197–207. doi: 10.1016/j.jcmgh.2019.04.013
   PubMed Web of Science ®Google Scholar
• Tousson A, Van Tine BA, Naren AP, et al. Characterization of CFTR expression and chloride channel activity in human endothelia. Am J Physiol Cell Physiol. 1998;275(6):C1555–C1564. doi: 10.1152/ajpcell.1998.275.6.C1555
   Web of Science ®Google Scholar
• Poore S, Berry B, Eidson D, et al. Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis. Chest. 2013;143(4):939–945. doi: 10.1378/chest.12-1934
   PubMed Web of Science ®Google Scholar
• Lindberg U, Svensson L, Hellmark T, et al. Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status. Thromb Res. 2018;162(September 2017):32–37. doi: 10.1016/j.thromres.2017.12.012
   PubMedGoogle Scholar
• Ortiz-Muñoz G, Yu MA, Lefrançais E, et al. Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation. J Clin Investig. 2020;130(4):2041–2053. doi: 10.1172/JCI129635
   PubMed Web of Science ®Google Scholar
• Beuers U, Hohenester S, Maillette de Buy Wenniger LJ, et al. The biliary HCO-3 Umbrella: aunifying hypothesis on pathogenetic and therapeutic aspects of fibrosing Cholangiopathies. Hepatology. 2010;52:1489–1496. doi: 10.1002/hep.23810
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Luketic VAC, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–814. doi: 10.1002/hep.23082
   PubMed Web of Science ®Google Scholar
• Colombo C, Crosignani A, Alicandro G, et al. Long-term Ursodeoxycholic acid therapy does not alter lithocholic acid levels in patients with cystic fibrosis with associated liver disease. J Paediatr. 2016;177:59–65.e1. doi: 10.1016/j.jpeds.2016.05.008
   PubMed Web of Science ®Google Scholar
• Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian group for the study of ursodeoxycholic acid in cystic fibrosis. Hepatology. 1996;23(6):1484–1490. doi: 10.1002/hep.510230627
   PubMed Web of Science ®Google Scholar
• Colombo C, Castellani MR, Balistreri WF, et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 1992;15(4):677–684. doi: 10.1002/hep.1840150421
   PubMed Web of Science ®Google Scholar
• Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998;27(1):166–174. doi: 10.1002/hep.510270126
   PubMed Web of Science ®Google Scholar
• Van der Feen C, Van der Doef HPJ, Van der Ent CK, et al. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros. 2016;15(6):834–838. doi: 10.1016/j.jcf.2016.07.009
   PubMed Web of Science ®Google Scholar
• Lepage G, Paradis K, Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Paediatr. 1997;130(1):52–58. doi: 10.1016/S0022-3476(97)70310-X
   PubMed Web of Science ®Google Scholar
• Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2017;2017(9). doi: 10.1002/14651858.CD000222.pub4
   Google Scholar
• Toledano MB, Mukherjee SK, Howell J, et al. The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. PLOS One. 2019;14(4):1–14. doi: 10.1371/journal.pone.0212779
   Web of Science ®Google Scholar
• Boëlle PY, Debray D, Guillot L, et al. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69(4):1648–1656. doi: 10.1002/hep.30148
   PubMed Web of Science ®Google Scholar
• Colombo C, Alicandro G, Oliver M, et al. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: a multicenter cohort study. J Cystic Fibrosis. 2022;21(2):220–226. doi: 10.1016/j.jcf.2021.03.014
   PubMed Web of Science ®Google Scholar
• Sellers ZM, Assis DN, Paranjape SM, et al. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology. 2023;79(5):1220–1238. doi: 10.1097/HEP.0000000000000646.
   PubMed Web of Science ®Google Scholar
• Beuers U, Trauner M, Jansen P, et al. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(S1):S25–37. doi: 10.1016/j.jhep.2015.02.023
   PubMedGoogle Scholar
• Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023;21(8):2076–2087. doi: 10.1016/j.cgh.2023.02.005
   PubMed Web of Science ®Google Scholar
• Taylor-Cousar JL, Robinson PD, Shteinberg M, et al. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet [Internet]. 2023;402(10408):1171–1184. doi: 10.1016/S0140-6736(23)01609-4.
   PubMed Web of Science ®Google Scholar
• Bower JK, Volkova N, Ahluwalia N, et al. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study. J Cystic Fibrosis. 2023;22(4):730–737. doi: 10.1016/j.jcf.2023.03.002
   PubMedGoogle Scholar
• Schwarzenberg SJ, Vu PT, Skalland M, et al. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI. J Cystic Fibrosis. [2023 Mar 1];22(2):282–289. doi: 10.1016/j.jcf.2022.10.003
   PubMed Web of Science ®Google Scholar
• Drummond D, Dana J, Berteloot L, et al. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR. J Cystic Fibrosis. 2022;21(2):212–219. doi: 10.1016/j.jcf.2021.07.018
   PubMed Web of Science ®Google Scholar
• Levitte S, Fuchs Y, Wise R, et al. Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis. Hepatol Commun. 2023 Feb;7(2):e0010–e0010. doi: 10.1097/HC9.0000000000000010
   PubMed Web of Science ®Google Scholar
• Calvo PL, Giugliano L, Evangelista A, et al. Effects of CFTR modulator therapies on liver stiffness and bile flow: A single-centre experience. J Hepatol. Elsevier B.V.; 2023;79(2):e76–8. doi: 10.1016/j.jhep.2023.02.006
   PubMed Web of Science ®Google Scholar
• Schnell A, Jüngert J, Klett D, et al. Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis. Liver Int. 2023;43(4):878–887. doi: 10.1111/liv.15544
   PubMed Web of Science ®Google Scholar
• Tewkesbury DH, Scott J, Barry PJ, et al. Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis. J Cystic Fibrosis. 2023;22(2):256–262. doi: 10.1016/j.jcf.2023.01.007
   PubMed Web of Science ®Google Scholar
• Tewkesbury DH, Athwal V, Bright-Thomas RJ, et al. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre. J Cystic Fibrosis. 2023 Mar 1;22(2):256–262. doi: 10.1016/j.jcf.2023.01.007
   PubMed Web of Science ®Google Scholar
• Colombo C, Zazzeron L, Claut L, et al. Liver function test abnormalities in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. J Cystic Fibrosis. 2022;21:S115–S116. doi: 10.1016/S1569-1993(22)00886-4
   PubMed Web of Science ®Google Scholar
• Patel N, Ansar M, Pham A, et al. Gilbert’s syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Pediatr Pulmonol. 2024. doi: 10.1002/ppul.26831
   Web of Science ®Google Scholar
• Lowry S, Mogayzel PJ, Oshima K, et al. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor. J Cystic Fibrosis. 2022;21(2):e99–e101. doi: 10.1016/j.jcf.2021.07.001
   PubMed Web of Science ®Google Scholar
• Salehi M, Iqbal M, Dube A, et al. Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio). Respir Med Case Rep. 2021 Jan 1;34:101553. doi: 10.1016/j.rmcr.2021.101553
   PubMed Web of Science ®Google Scholar
• Eldredge JA, Oliver MR, Ooi CY. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance receptor (CFTR) modulators. Paediatr Respir Rev. 2024;50:54–61. doi: 10.1016/j.prrv.2023.12.005
   PubMed Web of Science ®Google Scholar
• Burgel PR, Munck A, Durieu I, et al. Real-life safety and effectiveness of lumacaftor–ivacaftor in patients with cystic fibrosis. Am J Respir Crit Care Med. 2020;201(2):188–197. doi: 10.1164/rccm.201906-1227OC
   PubMed Web of Science ®Google Scholar
• Viswanathan L, Bachman E, Tian S, et al. Phase 1 Study to assess the safety and pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in subjects without cystic fibrosis with moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2022;47(6):817–825. doi: 10.1007/s13318-022-00791-8
   PubMed Web of Science ®Google Scholar
• Vonk SEM, Lub R, Weersink EJM, et al. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series. Clin Ther. 2023Feb 1. doi: 10.1016/S1569-1993(23)00672-0
   PubMed Web of Science ®Google Scholar
• Hong E, Li R, Shi A, et al. Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series. Pharmacotherapy. 2023 Apr;43(4):291–299. doi: 10.1002/phar.2786
   PubMed Web of Science ®Google Scholar
• Ramos KJ, Guimbellot JS, Valapour M, et al. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients. J Cystic Fibrosis. 2022;21(5):745–752. doi: 10.1016/j.jcf.2022.04.009
   PubMed Web of Science ®Google Scholar
• Colombo C, Ramm GA, Lindblad A, et al. Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators. J Cystic Fibrosis. 2023 Mar 1;22(2):263–265. doi: 10.1016/j.jcf.2023.01.012
   PubMed Web of Science ®Google Scholar
• Freedman SD, Katz MH, Parker EM, et al. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice. Proc Natl Acad Sci USA 1999;96(24):13995–14000. doi: 10.1073/pnas.96.24.13995
   PubMed Web of Science ®Google Scholar
• Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med. 2004;350(6):560–569. doi: 10.1056/NEJMoa021218
   PubMed Web of Science ®Google Scholar
• Beharry S, Ackerley C, Corey M, et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol. 2007;292(3):G839–G848. doi: 10.1152/ajpgi.00582.2005
   PubMed Web of Science ®Google Scholar
• Enguita M, Razquin N, Pamplona R, et al. The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells. Cell Death Dis. 2019;10(1):14. doi: 10.1038/s41419-018-1243-0
   PubMedGoogle Scholar
• Biervliet SV, Vanbillemont G, Biervliet JV, et al. Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients. Ann Nutr Metab. 2007;51(6):541–549. doi: 10.1159/000114208
   PubMed Web of Science ®Google Scholar
• Drzymała-Czyz S, Szczepanik M, Krzyzanowska P, et al. Serum phospholipid fatty acid composition in Cystic Fibrosis Patients with and without liver cirrhosis. Ann Nutr Metab. 2017;71(1–2):91–98. doi: 10.1159/000477913
   PubMed Web of Science ®Google Scholar
• Watson H, Stackhouse C. Omega-3 fatty acid supplementation for cystic fibrosis. Cochrane Database Syst Rev. 2020;2020(4). doi: 10.1002/14651858.CD002201.pub6
   Google Scholar
• Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30(5):1151–1158. doi: 10.1002/hep.510300527
   PubMed Web of Science ®Google Scholar
• Palaniappan SK, Than NN, Thein AW, et al. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev. 2020;2020(3). doi: 10.1002/14651858.CD012056.pub3
   Google Scholar
• Villanueva C, Albillos A, Genescà J, et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016;63(1):197–206. doi: 10.1002/hep.28264
   PubMed Web of Science ®Google Scholar
• Sinagra E, Perricone G, D’Amico M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39(6):557–568. doi: 10.1111/apt.12634
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62(11):1634–1641. doi: 10.1136/gutjnl-2012-304038
   PubMed Web of Science ®Google Scholar
• Zacharias AP, Jeyaraj R, Hobolth L, et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018;2018(10). doi: 10.1002/14651858.CD011510.pub2
   Google Scholar
• Gracia-Sancho J, Maeso-Díaz R, Fernández-Iglesias A, et al. New cellular and molecular targets for the treatment of portal hypertension. Hepatol Int. 2015;9:183–191. doi: 10.1007/s12072-015-9613-5
   PubMed Web of Science ®Google Scholar
• Sakiani S, Heller T, Koh C. Current and investigational drugs in early clinical development for portal hypertension. Front Med. 2022 Oct 10;9:974182. doi: 10.3389/fmed.2022.974182 PMID: 36300180; PMCID: PMC9589453.
   Web of Science ®Google Scholar
• Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53(4):702–712. doi: 10.1016/j.jhep.2010.04.025
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Villanueva C, Aracil C, et al. Addition of Simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160–1170.e3. doi: 10.1053/j.gastro.2016.01.004
   PubMed Web of Science ®Google Scholar
• Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of Cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–1530.e8. doi: 10.1016/j.cgh.2017.04.039
   PubMed Web of Science ®Google Scholar
• Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242–253. doi: 10.1002/hep.21673
   PubMed Web of Science ®Google Scholar
• Uschner FE, Ranabhat G, Choi SS, et al. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015;5(September):1–12. doi: 10.1038/srep14573
   Google Scholar
• Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836–1846. doi: 10.1002/hep.26338
   PubMed Web of Science ®Google Scholar
• Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69(6):1127–1138. doi: 10.1136/gutjnl-2019-318843
   PubMed Web of Science ®Google Scholar
• Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan 1;70(1):9–29. doi: 10.1136/gutjnl-2020-321790
   PubMed Web of Science ®Google Scholar
• Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015 Apr 1;64(4):531–537. doi: 10.1136/gutjnl-2014-308874
   PubMed Web of Science ®Google Scholar
• Runyon BA. Management of adult patients with ascites due to cirrhosis: An update. Hepatology. 2009 Jun;49(6):2087–2107. doi: 10.1002/hep.22853
   PubMed Web of Science ®Google Scholar
• Bai Z, Wang L, Wang R, et al. Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials. Hepatol Int. 2022 Dec 1;16(6):1468–1483. doi: 10.1007/s12072-022-10374-z
   PubMed Web of Science ®Google Scholar
• Ramadori P, Klag T, Malek NP, et al. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 2019;1(6):448–459. doi: 10.1016/j.jhepr.2019.10.001
   PubMedGoogle Scholar
• Queck A, Carnevale R, Uschner FE, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut. 2020;69(8):1535–1536. doi: 10.1136/gutjnl-2019-319044
   PubMed Web of Science ®Google Scholar
• Simon TG, Duberg AS, Aleman S, et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med. 2020;382(11):1018–1028. doi: 10.1056/NEJMoa1912035
   PubMed Web of Science ®Google Scholar
• Seifert LL, Schindler P, Sturm L, et al. Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study. Hepatol Int. 2022;16(3):658–668. doi: 10.1007/s12072-022-10330-x
   PubMed Web of Science ®Google Scholar
• Tripodi A, Primignani M, Mannucci PM, et al. Changing concepts of cirrhotic coagulopathy. Am J Gastroenterol. 2017;112(2):274–281. doi: 10.1038/ajg.2016.498
   PubMed Web of Science ®Google Scholar
• Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut. 2003;52(8):1206–1210. doi: 10.1136/gut.52.8.1206
   PubMed Web of Science ®Google Scholar
• Yee TT, Griffioen A, Sabin CA, et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut. 2000;47(6):845–851. doi: 10.1136/gut.47.6.845
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut. 2003;52(3):404–409. doi: 10.1136/gut.52.3.404
   PubMed Web of Science ®Google Scholar
• Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253–1260.e4. doi: 10.1053/j.gastro.2012.07.018
   PubMed Web of Science ®Google Scholar
• Garcia Cinca D. Multicenter Prospective randomized trial of the effect of rivaroxaban on survival and development of complications of portal hypertension in patients with cirrhosis (CIRROXABAN). Hospital Clinic of Barcelona: National Library of Medicine; 2019.
   Google Scholar
• Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081. doi: 10.1056/NEJMoa0907893
   PubMed Web of Science ®Google Scholar
• Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021;75:S67–81. doi: 10.1016/j.jhep.2020.11.013
   PubMed Web of Science ®Google Scholar
• Caraceni P, Vargas V, Solà E, et al. The use of Rifaximin in patients with cirrhosis. Hepatology. 2021;74(3):1660–1673. doi: 10.1002/hep.31708
   PubMed Web of Science ®Google Scholar
• Salehi S, Tranah TH, Lim S, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther. 2019;50(4):435–441. doi: 10.1111/apt.15326
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol (Australia). 2013;28(3):450–455. doi: 10.1111/jgh.12070
   PubMed Web of Science ®Google Scholar
• De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. [2022 Apr 1];76(4):959–974. doi: 10.1016/j.jhep.2021.12.022
   PubMed Web of Science ®Google Scholar
• Laine L, El-Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med. 1993;119(1):1–7. doi: 10.7326/0003-4819-119-1-199307010-00001
   PubMed Web of Science ®Google Scholar
• Onofrio F, Pereira Lima J, Azeredo A, et al. Efficacy of endoscopic treatments for acute esophageal variceal bleeding in Cirrhotics: systematic review and meta-analysis. ESGE Days 2019. 2019;51:1503–1514.
   Google Scholar
• Yin X, Zhang F, Guo H, et al. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients. Sci Rep. 2020;10(1):1–8. doi: 10.1038/s41598-020-65227-2
   PubMed Web of Science ®Google Scholar
• Lupi A, Barbiero G, Battistel M, et al. Transjugular intrahepatic portosystemic shunt in non-cirrhotic portal hypertension related to cystic fibrosis in a lung transplant patient. J Cyst Fibros. 2020;19(6):e45–7. doi: 10.1016/j.jcf.2020.06.019
   PubMed Web of Science ®Google Scholar
• Debray D, Lykavieris P, Gauthier F, et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol. 1999;31(1):77–83. doi: 10.1016/S0168-8278(99)80166-4
   PubMed Web of Science ®Google Scholar
• Linnane B, Oliver MR, Robinson PJ. Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series. Arch Dis Child. 2006;91(9):771–773. doi: 10.1136/adc.2006.093773
   PubMed Web of Science ®Google Scholar
• Louis D, Duc MLP, Reix P, et al. Partial splenectomy for portal hypertension in cystic fibrosis related liver disease. Pediatr Pulmonol. 2007;42(12):1173–1180. doi: 10.1002/ppul.20713
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Sellers ZM, Mazariegos G, et al. A multidisciplinary approach to pretransplant and posttransplant management of cystic fibrosis–associated liver disease. Liver Transpl. 2019 Apr 1;25(4):640–657. doi: 10.1002/lt.25421.
   PubMed Web of Science ®Google Scholar
• Milkiewicz P, Skiba G, Kelly D, et al. Transplantation for cystic fibrosis: outcome following early liver transplantation. J Gastroenterol Hepatol (Australia). 2002;17(2):208–213. doi: 10.1046/j.1440-1746.2002.02671.x
   PubMed Web of Science ®Google Scholar
• Morrell MR, Kiel SC, Pilewski JM. Organ transplantation for cystic fibrosis. Semin Respir Crit Care Med. 2019;40(6):842–856. doi: 10.1055/s-0039-3399554
   PubMed Web of Science ®Google Scholar
• Mendizabal M, Reddy KR, Cassuto J, et al. Liver transplantation in patients with cystic fibrosis: Analysis of united network for organ sharing data. Liver Transpl. 2011 Mar;17(3):243–250. doi: 10.1002/lt.22240
   PubMed Web of Science ®Google Scholar
• Kappler M, Espach C, Schweiger-Kabesch A, et al. Ursodeoxycholic acid therapy in cystic fibrosis liver disease – a retrospective long-term follow-up case-control study. Aliment Pharmacol Ther. 2012 Aug;36(3):266–273. doi: 10.1111/j.1365-2036.2012.05177.x
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Munck A, Carrion E, et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr. 2024 Feb 1;43(2):413–445. doi: 10.1016/j.clnu.2023.12.017.
   PubMed Web of Science ®Google Scholar